Identifying Drug Sensitivity Subnetworks with NETPHIX

Phenotypic heterogeneity in cancer is often caused by different patterns of genetic alterations. Understanding such phenotype-genotype relationships is fundamental for the advance of personalized medicine. One of the important challenges in the area is to predict drug response on a personalized level. The pathway-centric view of cancer significantly advanced the understanding of genotype-phenotype relationships. However, most of network identification methods in cancer focus on identifying subnetworks that include general cancer drivers or are associated with discrete features such as cancer subtypes, hence cannot be applied directly for the analysis of continuous features like drug response. On the other hand, existing genome wide association approaches do not fully utilize the complex proprieties of cancer mutational landscape. To address these challenges, we propose a computational method, named NETPHIX (NETwork-to-PHenotpe assocIation with eXlusivity), which aims to identify mutated subnetworks that are associated with drug response (or any continuous cancer phenotype). Utilizing properties such as mutual exclusivity and interactions among genes, we formulate the problem as an integer linear program and solve it optimally to obtain a set of genes satisfying the constraints. NETPHIX identified gene modules significantly associated with many drugs, including interesting response modules to MEK1/2 inhibitors in both directions (increased and decreased sensitivity to the drug) that the previous method, which does not utilize network information, failed to identify. The genes in the modules belong to MAPK/ERK signaling pathway, which is the targeted pathway of the drug.

[1]  J. Simon,et al.  PTEN Deficiency Mediates a Reciprocal Response to IGFI and mTOR Inhibition , 2014, Molecular Cancer Research.

[2]  Matteo Fischetti,et al.  Thinning out Steiner trees: a node-based model for uniform edge costs , 2017, Math. Program. Comput..

[3]  Richard M. Karp,et al.  DEGAS: De Novo Discovery of Dysregulated Pathways in Human Diseases , 2010, PloS one.

[4]  Florence Demenais,et al.  SigMod: an exact and efficient method to identify a strongly interconnected disease‐associated module in a gene network , 2017, Bioinform..

[5]  Teresa M. Przytycka,et al.  Understanding Genotype-Phenotype Effects in Cancer via Network Approaches , 2016, PLoS Comput. Biol..

[6]  Dorit S. Hochbaum,et al.  Efficient algorithms to discover alterations with complementary functional association in cancer , 2018, RECOMB.

[7]  Eli Upfal,et al.  Discovery of Mutated Subnetworks Associated with Clinical Data in Cancer , 2011, Pacific Symposium on Biocomputing.

[8]  Xiaoting Yu,et al.  Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer , 2018, Clinical Cancer Research.

[9]  Marco Chiarandini,et al.  An Efficient Branch and Cut Algorithm to Find Frequently Mutated Subnetworks in Cancer , 2016, WABI.

[10]  Teresa M. Przytycka,et al.  Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..

[11]  Phillip W Iversen,et al.  Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. , 2019 .

[12]  Francesco Iorio,et al.  Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy , 2016, Scientific Reports.

[13]  M. Fukumoto,et al.  KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer , 2008, British Journal of Cancer.

[14]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[15]  J. Guevara,et al.  The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain , 2017, Oxidative medicine and cellular longevity.

[16]  Roded Sharan,et al.  BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions , 2017, PLoS Comput. Biol..

[17]  Dennis Vitkup,et al.  Diverse types of genetic variation converge on functional gene networks involved in schizophrenia , 2012, Nature Neuroscience.

[18]  Michael P. Morrissey,et al.  Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.

[19]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[20]  Han C. Dan,et al.  Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor. , 2019, American journal of cancer research.

[21]  Teresa M. Przytycka,et al.  WeSME: uncovering mutual exclusivity of cancer drivers and beyond , 2016, Bioinform..

[22]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[23]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[24]  Lucio Crinò,et al.  Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. , 2013, Future oncology.

[25]  Caroline Robert,et al.  P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. , 2017, European journal of cancer.

[26]  Trey Ideker,et al.  Genotype to phenotype via network analysis. , 2013, Current opinion in genetics & development.

[27]  P. Haluska,et al.  Can we unlock the potential of IGF-1R inhibition in cancer therapy? , 2014, Cancer treatment reviews.

[28]  Hongzhe Li,et al.  In Response to Comment on "Network-constrained regularization and variable selection for analysis of genomic data" , 2008, Bioinform..

[29]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[30]  Fei Huang,et al.  IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines , 2014, Molecular Cancer Therapeutics.

[31]  Yiming Wang,et al.  On imposing connectivity constraints in integer programs , 2017, Mathematical Programming.

[32]  Julian Downward,et al.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. , 2013, Cancer discovery.

[33]  Salim A. Chowdhury,et al.  IDENTIFICATION OF COORDINATELY DYSREGULATED SUBNETWORKS IN COMPLEX PHENOTYPES by SALIM , 2010 .

[34]  Wei Zheng,et al.  dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks , 2011, Bioinform..

[35]  Teresa M. Przytycka,et al.  Module Cover - A New Approach to Genotype-Phenotype Studies , 2012, Pacific Symposium on Biocomputing.

[36]  Wei Zhang,et al.  Classifying tumors by supervised network propagation , 2018, Bioinform..

[37]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[38]  Chris Sander,et al.  Using MEMo to Discover Mutual Exclusivity Modules in Cancer , 2013, Current protocols in bioinformatics.

[39]  C J Gomer,et al.  Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. , 2001, Cancer research.

[40]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[41]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[42]  Gabriela Alexe,et al.  Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.

[43]  Niko Beerenwinkel,et al.  TiMEx: a waiting time model for mutually exclusive cancer alterations , 2015, Bioinform..

[44]  Teresa M. Przytycka,et al.  MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types , 2015, Bioinform..

[45]  T. Miller,et al.  Therapeutic targeting of cancers with loss of PTEN function. , 2014, Current drug targets.

[46]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[47]  H. Lenz,et al.  The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. , 2011, Cancer research.

[48]  Yoshinobu Kawahara,et al.  Efficient network-guided multi-locus association mapping with graph cuts , 2012, Bioinform..

[49]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[50]  Edward A. Sausville,et al.  P1-12-20: The Safety and Tolerability of Vorinostat in Combination with Lapatinib in Advanced Solid Tumors. , 2011 .